These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18991665)

  • 1. Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases.
    De Vivo G; Gentile V
    CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):370-5. PubMed ID: 18991665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases.
    De Vivo G; Di Lorenzo R; Ricotta M; Gentile V
    Curr Med Chem; 2009; 16(36):4767-73. PubMed ID: 19929789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
    Martin A; Giuliano A; Collaro D; De Vivo G; Sedia C; Serretiello E; Gentile V
    Amino Acids; 2013 Jan; 44(1):111-8. PubMed ID: 21938398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
    Iannaccone M; Titta F; Serretiello E; Monfregola M; Gentile V
    Recent Pat CNS Drug Discov; 2014; 9(2):76-84. PubMed ID: 25386917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
    Martin A; De Vivo G; Ricotta M; Iannuzzi M; Gentile V
    Recent Pat CNS Drug Discov; 2010 Nov; 5(3):195-202. PubMed ID: 20636272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
    Iannaccone M; Serretiello E; De Vivo G; Martin A; Stefanile A; Titta F; Gentile V
    Recent Pat CNS Drug Discov; 2013 Aug; 8(2):161-8. PubMed ID: 23688272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transglutaminase-catalyzed reactions responsible for the pathogenesis of celiac disease and neurodegenerative diseases: from basic biochemistry to clinic.
    Martin A; Romito G; Pepe I; De Vivo G; Merola MR; Limatola A; Gentile V
    Curr Med Chem; 2006; 13(16):1895-902. PubMed ID: 16842200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transglutaminase activity as a possible therapeutical target in neurodegenerative diseases.
    Iannaccone M; Titta F; Serretiello E; De Vivo G; Martin A; Gentile V
    Recent Pat CNS Drug Discov; 2013 Dec; 8(3):235-42. PubMed ID: 24286449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physio-pathological roles of transglutaminase-catalyzed reactions.
    Ricotta M; Iannuzzi M; Vivo GD; Gentile V
    World J Biol Chem; 2010 May; 1(5):181-7. PubMed ID: 21541002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible physiopathological roles of the transglutaminase activity in the etiopathogenesis of human neurodegenerative diseases.
    Titta F; Iannaccone M; Martin A; Gentile V
    Recent Pat CNS Drug Discov; 2014; 9(2):101-9. PubMed ID: 24924102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of transglutaminase-catalyzed reactions in the post-translational modifications of proteins responsible for immunological disorders.
    De Vivo G; Martin A; Trotta T; Gentile V
    Inflamm Allergy Drug Targets; 2008 Mar; 7(1):24-9. PubMed ID: 18473897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Transglutaminase and neurodegenerative diseases].
    Liu Z; Zeng J; Zeng S; Tang B; Wang J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Aug; 32(4):562-6. PubMed ID: 26252108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transglutaminases - possible drug targets in human diseases.
    Gentile V; Cooper AJ
    Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):99-104. PubMed ID: 15078184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible role of the transglutaminases in the pathogenesis of Alzheimer's disease and other neurodegenerative diseases.
    Martin A; De Vivo G; Gentile V
    Int J Alzheimers Dis; 2011 Feb; 2011():865432. PubMed ID: 21350675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms responsible for the involvement of tissue transglutaminase in human diseases: Celiac Disease.
    Amantea G; Cammarano M; Zefferino L; Martin A; Romito G; Piccirillo M; Gentile V
    Front Biosci; 2006 Jan; 11():249-55. PubMed ID: 16146729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiological roles of transglutaminase - catalyzed reactions in the pathogenesis of human diseases.
    Martin A; De Vivo G; Iannaccone M; Stefanile A; Serretiello E; Gentile V
    Inflamm Allergy Drug Targets; 2012 Aug; 11(4):278-84. PubMed ID: 22680626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysine-rich histone (H1) is a lysyl substrate of tissue transglutaminase: possible involvement of transglutaminase in the formation of nuclear aggregates in (CAG)(n)/Q(n) expansion diseases.
    Cooper AJ; Wang J; Pasternack R; Fuchsbauer HL; Sheu RK; Blass JP
    Dev Neurosci; 2000; 22(5-6):404-17. PubMed ID: 11111157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transglutaminase-catalyzed crosslinking in neurological disease: from experimental evidence to therapeutic inhibition.
    Hoffner G; André W; Vanhoutteghem A; Souès S; Djian P
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):217-31. PubMed ID: 19811443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability.
    Cooper AJ; Sheu KF; Burke JR; Strittmatter WJ; Gentile V; Peluso G; Blass JP
    J Neurochem; 1999 Mar; 72(3):889-99. PubMed ID: 10037459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transglutaminase-dependent formation of protein aggregates as possible biochemical mechanism for polyglutamine diseases.
    Violante V; Luongo A; Pepe I; Annunziata S; Gentile V
    Brain Res Bull; 2001 Oct-Nov 1; 56(3-4):169-72. PubMed ID: 11719247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.